Third Harmonic Bio Initiates Strategic Review, Lays Off 50% Staff Citing Competitive Landscape
Third Harmonic Bio plans a Phase 2 trial for THB335 in chronic spontaneous urticaria and will reduce its workforce by 50% ...
Yahoo Finance6d
Third Harmonic Bio Initiates Strategic Review, Lays Off 50% Staff Citing Competitive Landscape
On Tuesday, Third Harmonic Bio, Inc. (NASDAQ:THRD) revealed results from its Phase 1 single and multiple ascending dose (SAD/MAD) trial of THB335 in healthy volunteers. The company says the data ...
Biotech Alert: Searches spiking for these stocks today
These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...
Benzinga.com6d
Benzinga Briefs
The company says the data are expected to support the advancement of THB335 into a Phase 2 trial in chronic spontaneous urticaria (CSU). Dose-dependent reductions in serum tryptase, a biomarker of ...
Investing4d
Third Harmonic Bio Inc (THRD)
Third Harmonic (NASDAQ:HLIT) Bio, Inc. (THRD) has experienced a notable downturn, touching a 52-week low of $5.58. This latest price point reflects a significant ...